# Efficacy and Safety of HB-1 for Panic Disorder

> **NCT06483789** · PHASE2 · RECRUITING · sponsor: **HB BioTech, LLC** · enrollment: 240 (estimated)

## Conditions studied

- Panic Disorder
- Mental Illness

## Interventions

- **DRUG:** HB-1
- **DRUG:** Telmisartan Only Product in Oral Dose Form
- **DRUG:** Verapamil Only Product in Oral Dose Form
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06483789
- **Lead sponsor:** HB BioTech, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-29
- **Primary completion:** 2027-01
- **Final completion:** 2027-02
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06483789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06483789, "Efficacy and Safety of HB-1 for Panic Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06483789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*